查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2000761

中樞神經系統治療市場：全球市場預測（依藥物類別、適應症、給藥途徑、作用機制、最終用戶和分銷管道分類），2026年至2032年

Central Nervous System Therapeutics Market by Drug Class, Disease Indication, Route Of Administration, Mechanism Of Action, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，中樞神經系統治療市場價值將達到 1,523.3 億美元，到 2026 年將成長至 1,635.2 億美元，到 2032 年將達到 2,535.4 億美元，複合年成長率為 7.54%。

主要市場統計數據
基準年 2025 1523.3億美元
預計年份：2026年 1635.2億美元
預測年份 2032 2535.4億美元
複合年成長率 (%) 7.54%

隨著創新、人口結構變化和醫療保健服務體系的變革重塑治療模式，中樞神經系統療法正處於十字路口。

受人口結構壓力和人們對神經精神疾病及心理疾病日益變化的社會期望的驅動，中樞神經系統（CNS）療法正在經歷根本性的重新定義。神經系統疾病、精神疾病、神經血管疾病和創傷性中樞神經系統疾病共同造成了全球範圍內相當大比例的殘疾，並且由於人口老化、生活方式改變和診斷能力的提高，其臨床和經濟負擔正在不斷加重。在此背景下，治療研發的重點不再僅限於症狀控制，而是日益轉向緩解疾病、神經保護和長期功能恢復。

科學、技術和監管方面的變革性變化正在重新定義中樞神經系統療法的競爭格局。

科學、技術、監管和病人期望等方面的許多變革正在重塑中樞神經系統（CNS）治療的格局。從科學角度來看，儘管過去的研究重點是利用小分子調節神經傳導物質，但如今基於機制的疾病生物學觀點正逐漸佔據主導地位。基因組學、蛋白質組學和神經影像學的進步正在闡明阿茲海默症、思覺失調症、癲癇和多發性硬化症等疾病的分子基礎。因此，除了具有更高選擇性和安全性的小分子化合物外，開發平臺也越來越專注於基因治療、單株抗體和胜肽療法等標靶治療方法。

到 2025 年，美國關稅的累積變化正在重塑中樞神經系統 (CNS) 供應鏈、成本結構和長期製造策略。

美國計劃於2025年實施的關稅結構調整，對中樞神經系統（CNS）療法的生態系統產生了複雜且累積的影響。雖然許多CNS療法是在美國本土生產或加工的，但支撐這些治療方法的活性成分、輔料、包裝材料和特殊給藥技術卻依賴全球化的供應鏈。對主要貿易夥伴提供的化學品、生物製藥和醫用級材料分階段調整關稅，可能會增加生產成本，並使籌資策略更加複雜，尤其對於先進的基因療法、單株抗體和特殊注射藥物而言。

細分分析揭示了藥物類別、適應症、給藥途徑、作用機制和臨床實踐優先事項的變化。

藥物類別細分分析揭示了當前市場現狀：治療方法治療方法在重新定義自身角色。抗憂鬱症和抗精神病藥物仍然是治療重度憂鬱症、焦慮症、思覺失調症和躁鬱症的核心藥物，但需要提高其耐受性和功能性療效。抗癲癇藥物仍然是治療癲癇的必需藥物，在神經性疼痛和某些情緒障礙的治療中也得到了越來越廣泛的應用。同時，抗焦慮藥物可以短期緩解症狀，但其依賴性和安全性需要更嚴格的監測。麻醉劑和鎮痛藥在外科手術和手術全期護理中發揮著至關重要的作用，同時也用於治療與中樞神經系統創傷和神經退化性疾病相關的慢性疼痛，因此需要對製劑和作用機制進行創新，以降低濫用風險。中樞神經系統興奮劑在注意力不足/過動症（ADHD）和某些認知障礙的治療中佔據著穩固的地位，人們仍在努力平衡其療效與心血管風險和濫用風險。

各大洲的區域差異影響中樞神經系統療法的取得、創新和應用模式。

中樞神經系統 (CNS) 療法的區域趨勢反映了美洲、歐洲、中東和非洲以及亞太地區在人口結構、醫療基礎設施、法規環境和投資能力方面的差異。在美洲，尤其是北美，高額的醫療費用支出、完善的報銷體系和強大的臨床研究網路為創新 CNS 療法的引入創造了有利條件。在神經退化性神經退化性疾病和精神疾病治療領域的專業卓越中心的支持下，該地區往往能夠率先將先進的生物製藥、基因療法和長效注射劑推向市場。同時，對精神健康和疼痛管理實踐的監管力度不斷加強，推動了對安全性更高、且在真實臨床實踐中具有可靠療效證據的治療方法的需求。

在中樞神經系統治療領域，那些結合了深厚的科學知識、協作系統和以患者為中心的模式的公司正在獲得競爭優勢。

中樞神經系統（CNS）療法的競爭格局由大型製藥企業、中型專業公司和新興生物技術公司組成，每家公司都擁有其獨特的能力和策略重點。成熟的跨國公司通常擁有涵蓋抗憂鬱症、抗精神病藥物、抗驚厥藥、麻醉劑、鎮痛藥、抗焦慮藥和中樞神經系統興奮劑等廣泛產品組合，並利用其全球商業基礎設施在高發適應症領域保持市場地位。這些公司在專注於產品生命週期管理、漸進式創新和地理擴張的同時，也會選擇性地投資於單株抗體和基因療法等先進治療方法，以治療影響深遠的神經退化性疾病。

可操作的策略有助於中樞神經系統 (CNS) 行業的領導者將創新、韌性和以患者為中心的執行力結合起來，從而產生持久的影響。

中樞神經系統治療領域的領導企業面臨著一個關鍵機遇，即如何將科學進步和不斷發展的治療模式轉化為永續的策略優勢。首要任務是使研發組合與神經退化性疾病、精神疾病、神經血管疾病和中樞神經系統創傷等領域最緊迫的未滿足需求相符。這需要對基因療法、單株抗體、胜肽類藥物和新一代小分子藥物能夠真正改變疾病進程的領域進行嚴格評估，而不僅僅是改善症狀。企業應優先考慮那些機制理解正在快速發展且法規環境和支付環境對創新治療方法持開放態度的適應症。

我們強大而多方面的調查方法，能夠提供對中樞神經系統治療市場環境的精確且基於證據的觀點。

本中樞神經系統治療分析的調查方法融合了多種互補途徑，以確保對市場環境進行全面可靠的評估。其核心是對同行評審的臨床文獻、監管文件和政策相關出版物進行系統性回顧，這些文獻反映了神經退化性疾病、精神疾病、神經血管疾病和中樞神經系統創傷治療標準的演變。這包括對已通過核准治療方法和後期研發管線資產的數據進行系統性檢驗，重點在於作用機制、給藥途徑、安全性和有效性特徵，以及（如有）真實世界使用模式。

中樞神經系統療法正進入一個關鍵時期，科學突破必須與韌性、可及性和以病人為中心的照護結合。

中樞神經系統（CNS）療法正步入一個充滿前所未有的潛力和持續複雜性的時期。我們對神經退化性疾病、精神疾病、神經血管疾病和創傷性中樞神經系統疾病背後的分子機制的理解不斷加深，推動了靶向小分子化合物、基因療法、單株抗體和基於胜肽的干涉措施的研發。同時，抗憂鬱症、抗精神病藥、抗驚厥藥、麻醉藥、止痛藥、抗焦慮藥和中樞神經麻醉劑等傳統藥物治療方法，治療方法重新定義臨床醫生、醫療保健系統和產業相關人員管理中樞神經系統疾病的方式。

然而，科學進步

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 中樞神經系統治療藥物市場：依藥物類別分類

  • 抗憂鬱症
  • 抗精神病藥物
  • 抗驚厥藥物
  • 抗焦慮藥物
  • 麻醉劑
  • 止痛藥
  • 中樞神經系統興奮劑

第9章 中樞神經系統治療市場：依疾病適應症分類

  • 神經退化性疾病
    • 阿茲海默症
    • 帕金森氏症
    • 亨丁頓舞蹈症
    • 多發性硬化症
  • 精神疾病
    • 重度憂鬱症
    • 焦慮症
    • 思覺失調症
    • 躁鬱症
  • 神經血管疾病
    • 中風
    • 腦動脈瘤
  • 中樞神經系統創傷
    • 創傷性腦損傷（TBI）
    • 脊髓損傷

第10章 中樞神經系統治療藥物市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 經皮

第11章 中樞神經系統治療藥物市場（依作用機轉分類）

  • 基因治療
  • 單株抗體
  • 胜肽
  • 低分子化合物

第12章 中樞神經系統治療市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第13章 中樞神經系統治療市場：依通路分類

  • 物理藥房
  • 網路藥房

第14章 中樞神經系統治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 中樞神經系統治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 中樞神經系統治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國中樞神經系統治療市場

第18章：中國中樞神經系統治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AC Immune SA
  • Acadia Pharmaceuticals, Inc.
  • Alkermes plc
  • Amgen Inc.
  • Anavex Life Sciences Corp.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • H. Lundbeck A/S
  • Ipsen SA
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Neumora Therapeutics, Inc.
  • Neurocrine Biosciences, Inc.
  • Neurona Therapeutics Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Supernus Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris Inc.
Product Code: MRR-02026C4C9A19

The Central Nervous System Therapeutics Market was valued at USD 152.33 billion in 2025 and is projected to grow to USD 163.52 billion in 2026, with a CAGR of 7.54%, reaching USD 253.54 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 152.33 billion
Estimated Year [2026] USD 163.52 billion
Forecast Year [2032] USD 253.54 billion
CAGR (%) 7.54%

Central nervous system therapeutics at a crossroads as innovation, demographics, and care delivery reshape treatment paradigms

Central nervous system therapeutics are undergoing a fundamental redefinition as clinical innovation converges with demographic pressure and changing societal expectations of mental and neurological health. Neurological, psychiatric, neurovascular, and traumatic CNS conditions together account for a substantial share of global disability, and their clinical and economic burden is intensifying as populations age, lifestyles shift, and diagnostic capabilities improve. Against this backdrop, therapeutic development is no longer focused solely on symptom control; instead, it is increasingly oriented toward disease modification, neuroprotection, and long-term functional recovery.

This transformation is visible across the full therapeutic continuum, from antidepressants and antipsychotics to anticonvulsants, anesthetics, pain relievers, anxiolytics, and CNS stimulants. Traditional small-molecule agents still anchor treatment in many indications, but they now coexist with targeted biologics, gene-based approaches, and peptide therapeutics that aim to intervene earlier and more precisely in disease pathways. The market is further shaped by rising awareness of mental health, improved screening for neurodegenerative diseases such as Alzheimer's and Parkinson's, and a growing emphasis on timely intervention in stroke and traumatic brain injury.

In parallel, care delivery models are evolving to accommodate chronic, relapsing courses of CNS conditions and to address issues of adherence, safety, and quality of life. Hospitals remain central to acute management of neurovascular events and CNS trauma, while clinics and home care environments are assuming a greater role in the longitudinal management of psychiatric disorders, multiple sclerosis, and other chronic neurological diseases. As treatment advances spread, distribution channels are adapting, with both offline and online pharmacies playing distinct roles in access, affordability, and continuity of therapy.

Taken together, these shifts are creating a more complex, data-driven, and outcomes-focused environment. Stakeholders ranging from pharmaceutical manufacturers and biotech innovators to health systems, payers, and policymakers are reevaluating how they develop, deploy, and evaluate CNS therapeutics. This report provides a structured examination of the major scientific, regulatory, economic, and commercial forces reshaping this landscape, offering a foundation for strategic decisions in a domain where unmet need remains substantial and the pace of innovation is accelerating.

Transformative scientific, technological, and regulatory shifts are redefining competitive dynamics in CNS therapeutics

The landscape for CNS therapeutics is being reshaped by several transformative shifts that span science, technology, regulation, and patient expectations. On the scientific front, the historical focus on neurotransmitter modulation through small molecules is giving way to a more mechanistic view of disease biology. Advancements in genomics, proteomics, and neuroimaging are illuminating the molecular underpinnings of conditions such as Alzheimer's disease, schizophrenia, epilepsy, and multiple sclerosis. As a result, development pipelines increasingly feature targeted modalities, including gene therapy, monoclonal antibodies, and peptide-based therapeutics, alongside refined small molecules designed with better selectivity and safety profiles.

Technology is amplifying these scientific gains. Digital tools such as wearable sensors, smartphone-based cognitive assessments, and remote monitoring platforms are generating real-world data that can inform both clinical development and post-market evaluation. This data-rich environment allows developers to track subtle changes in disease progression, adherence, and functional outcomes, particularly important for psychiatric disorders and neurodegenerative diseases where conventional endpoints may evolve slowly. Moreover, advanced analytics and artificial intelligence are being applied to identify novel targets, predict treatment response, and optimize trial design, potentially reducing the time and risk associated with CNS drug development.

Regulatory and reimbursement frameworks are also evolving in response to these innovations. Agencies in major markets are demonstrating a greater openness to adaptive trial designs, surrogate endpoints, and real-world evidence, especially for high-burden, high-unmet-need conditions such as Huntington's disease, treatment-resistant depression, and spinal cord injury. At the same time, payers are increasingly demanding robust evidence of comparative effectiveness and value, pushing manufacturers to integrate health economics and outcomes research into their development strategies from an earlier stage. Outcome-based agreements and risk-sharing models are emerging in some markets, particularly around high-cost biologics and gene-based therapies.

Patient and caregiver expectations are shifting just as rapidly. There is growing recognition of mental health as a core component of overall wellbeing, reducing stigma and driving higher rates of diagnosis and treatment-seeking for anxiety disorders, major depressive disorder, and bipolar disorder. Patients today expect therapies that not only manage symptoms but also preserve cognitive function, support independence, and minimize treatment-related burdens such as complex dosing or intrusive side effects. This is intensifying interest in routes of administration that support adherence, including convenient oral regimens and user-friendly injectable or transdermal formulations.

Altogether, these shifts are creating both opportunities and challenges. Incumbent drug classes face pressure to demonstrate differentiated value, while emerging modalities must prove long-term safety, durability of effect, and affordability. Companies that integrate advanced science with digital tools, align early with evolving regulatory and payer expectations, and elevate patient-centric design throughout the development process are positioned to lead in this new era of CNS therapeutics.

Cumulative 2025 United States tariff shifts reshape CNS supply chains, cost structures, and long-term manufacturing strategies

The evolving structure of tariffs planned for implementation in the United States in 2025 is exerting a complex, cumulative influence on the CNS therapeutics ecosystem. While many CNS drugs are manufactured or finished domestically, globalized supply chains underlie the active pharmaceutical ingredients, excipients, packaging components, and specialized delivery technologies on which these therapies depend. Incremental tariff adjustments on chemicals, biologic inputs, and medical-grade materials sourced from key trading partners can increase production costs and complicate procurement strategies, particularly for advanced gene therapies, monoclonal antibodies, and specialized injectables.

For manufacturers of antidepressants, antipsychotics, anticonvulsants, anesthetics, pain relievers, anxiolytics, and CNS stimulants, the impact is rarely uniform. Companies with diversified supplier bases and robust domestic capabilities may be able to absorb or reallocate the cost burden more effectively, while firms that rely heavily on specific international suppliers may face sharper cost increases or supply volatility. Over time, these cumulative pressures can encourage reshoring or nearshoring of critical production steps, spur investment in automation, and accelerate qualification of alternative suppliers, though such adjustments require significant capital and regulatory alignment.

The ripple effects of tariffs extend beyond manufacturing to affect pricing strategies, market access, and competitive positioning. Higher input costs can create upward pressure on prices, particularly for branded therapies with complex manufacturing processes or cold-chain requirements. However, payers and health systems in the United States are scrutinizing CNS drug expenditures closely, especially in high-prevalence psychiatric conditions and chronic neurodegenerative diseases where long-term treatment is standard. This tension constrains the degree to which cost increases can be passed through, compelling companies to seek savings via operational efficiencies, portfolio optimization, or differential pricing across channels.

Tariffs also intersect with broader geopolitical and trade considerations that shape long-term supply security. Organizations managing critical therapies for stroke, traumatic brain injury, spinal cord injury, and other acute CNS conditions are particularly sensitive to any risk that could disrupt timely availability. As a result, many are reevaluating inventory strategies, safety stock policies, and strategic partnerships to buffer against potential delays or cost spikes linked to tariff changes. Contract manufacturing organizations and logistics providers are adapting accordingly, seeking to offer more resilient, tariff-aware service models.

Although tariffs themselves do not directly alter clinical demand for CNS therapies, their cumulative effects on cost structures, supply chain resilience, and investment priorities can indirectly influence which therapies are prioritized, how quickly novel modalities are scaled, and how aggressively companies compete in price-sensitive segments. Stakeholders that proactively model these tariff-related scenarios and incorporate them into risk management, procurement planning, and long-term manufacturing strategy will be better equipped to maintain continuity of care while preserving margins in an increasingly complex trade environment.

Segmentation insights reveal shifting priorities across drug classes, indications, delivery routes, mechanisms, and care settings

Segmentation by drug class reveals a market in which both established and emerging therapies are redefining their roles. Antidepressants and antipsychotics remain central to the management of major depressive disorder, anxiety disorders, schizophrenia, and bipolar disorder, yet they are under pressure to deliver better tolerability and functional outcomes. Anticonvulsants continue to be indispensable for epilepsy and are increasingly leveraged in neuropathic pain and certain mood disorders, while anxiolytics provide short-term relief but face heightened scrutiny around dependence and safety. Anesthetics and pain relievers occupy a critical position in surgical and perioperative care as well as in chronic pain associated with CNS trauma and neurodegenerative disease, prompting innovation in formulations and mechanisms that reduce abuse potential. CNS stimulants maintain a strong foothold in attention-related and certain cognitive conditions, with ongoing efforts to balance efficacy with cardiovascular and misuse risks.

Disease indication segmentation underscores divergent dynamics across neurodegenerative disorders, psychiatric disorders, neurovascular diseases, and CNS trauma. Within neurodegenerative disorders, the landscape is especially active in Alzheimer's disease and Parkinson's disease, where disease-modifying approaches, including monoclonal antibodies and gene-targeted therapies, are being pursued alongside symptomatic agents. Huntington's disease and multiple sclerosis exemplify the move toward highly specialized, mechanism-based treatments that demand sophisticated monitoring and support programs. In psychiatric disorders, the sheer prevalence of major depressive disorder and anxiety disorders keeps demand high for both first-line and adjunctive therapies, while schizophrenia and bipolar disorder highlight the need for long-acting formulations and better adherence solutions. Neurovascular diseases such as stroke and cerebral aneurysm require fast-acting interventions and rigorous secondary prevention regimens, driving interest in acute neuroprotective strategies and chronic risk management. CNS trauma, encompassing traumatic brain injury and spinal cord injury, continues to attract research into neuroregeneration, inflammation control, and functional rehabilitation.

Segmentation by route of administration illustrates how convenience, adherence, and clinical context shape therapeutic choices. Oral formulations dominate in many psychiatric and chronic neurological indications due to ease of use and broad patient acceptance, yet their effectiveness is closely tied to adherence. Injectable therapies are gaining ground for biologics, gene therapies, and long-acting formulations across neurodegenerative and psychiatric conditions, providing sustained exposure and potentially improved outcomes, albeit with higher administration complexity. Transdermal delivery offers an alternative for patients with swallowing difficulties or gastrointestinal intolerance and is increasingly considered in long-term management of movement disorders and chronic pain.

When viewed through the lens of mechanism of action, the contrast between traditional small molecules and advanced modalities becomes more pronounced. Small molecules continue to account for the majority of prescriptions, especially in high-prevalence psychiatric and seizure disorders, due to their oral availability, cost profile, and well-established regulatory pathways. However, gene therapy is emerging as a transformative approach in select monogenic neurodegenerative and neuromuscular conditions, signaling a shift toward potential one-time or infrequent treatments with durable benefit. Monoclonal antibodies are gaining traction in conditions such as multiple sclerosis and Alzheimer's disease, where they target specific immune or protein-aggregation pathways. Peptides offer a middle ground, enabling high specificity with diverse administration options, and are increasingly explored for neuroendocrine and neuromodulatory targets.

End user segmentation highlights how care settings influence therapy selection, monitoring, and support services. Hospitals are central to acute management of stroke, cerebral aneurysm interventions, neurosurgical procedures, and severe CNS trauma, often initiating complex regimens that are later continued in outpatient settings. Clinics provide the backbone for chronic management of psychiatric disorders, epilepsy, and multiple sclerosis, coordinating medication adjustments, counseling, and multidisciplinary care. Home care is expanding in importance as health systems seek to shift stable patients out of institutional settings, leveraging telemedicine, remote monitoring, and home-administered therapies to maintain continuity of care for conditions such as Alzheimer's disease, Parkinson's disease, and long-term post-injury recovery.

Finally, segmentation by distribution channel reveals a dual-track environment in which offline pharmacies and online pharmacies play complementary roles. Brick-and-mortar outlets remain essential for acute prescriptions, complex counseling needs, and populations less inclined to use digital platforms, particularly in regions with limited broadband penetration. Online pharmacies, on the other hand, are becoming increasingly influential for repeat prescriptions, chronic psychiatric and neurological medications, and therapies where privacy, pricing transparency, and home delivery are valued. This diversification in distribution is reshaping brand strategies, adherence programs, and patient engagement models across the CNS therapeutics spectrum.

Regional variations across continents shape access, innovation, and adoption patterns for central nervous system therapeutics

Regional dynamics in CNS therapeutics reflect differences in demographics, healthcare infrastructure, regulatory environments, and investment capacity across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, particularly in North America, high healthcare spending, established reimbursement systems, and strong clinical research networks create fertile ground for the introduction of innovative CNS therapies. Advanced biologics, gene therapies, and long-acting injectable formulations are often launched early in this region, supported by specialized centers of excellence in neurodegenerative and psychiatric care. At the same time, there is growing scrutiny of mental health and pain management practices, driving demand for therapies with improved safety profiles and robust evidence of real-world effectiveness.

In Europe, Middle East & Africa, the landscape is more heterogeneous but characterized in many European countries by universal or near-universal coverage and strong regulatory oversight. European markets are often early adopters of guideline-based care for conditions such as multiple sclerosis, epilepsy, and major depressive disorder, with structured pathways that can facilitate consistent use of effective therapies. However, price controls and health technology assessments may moderate the speed and breadth of uptake for high-cost monoclonal antibodies and gene-based treatments, compelling manufacturers to tailor value propositions to each country's assessment criteria. In parts of the Middle East and Africa, CNS care is constrained by resource limitations, uneven access to specialists, and lower awareness of mental health and neurodegenerative diseases, though investment in tertiary care centers and diagnostic infrastructure is slowly improving the situation.

Asia-Pacific presents a different set of dynamics, driven by rapid demographic shifts, urbanization, and expanding middle-income populations. Several countries in this region are experiencing a surge in age-related neurodegenerative diseases alongside persistent gaps in mental health services. While access to the most advanced biologics and gene therapies may be uneven, there is strong demand for cost-effective antidepressants, antipsychotics, anticonvulsants, and pain relievers. Health systems in Japan, South Korea, Australia, and increasingly China are investing in CNS research and specialized care pathways, fostering local innovation and clinical trials. Meanwhile, emerging economies across Southeast Asia and South Asia are focusing on strengthening primary and secondary care capabilities for stroke, epilepsy, and common psychiatric disorders.

Digital health adoption adds another layer of differentiation across regions. In the Americas and parts of Asia-Pacific, telepsychiatry and remote neurology consultations are gaining traction, enhancing access to specialized care for rural and underserved populations. Europe is integrating digital tools into care pathways more gradually but with an emphasis on interoperability and data protection. In the Middle East and Africa, mobile platforms are increasingly used to expand mental health support where formal services are scarce. These variations influence how CNS therapies are prescribed, monitored, and supported, especially in chronic conditions that benefit from close, continuous engagement.

Across all regions, policy initiatives aimed at destigmatizing mental illness, improving early diagnosis of dementia and movement disorders, and expanding stroke and trauma care capacity are converging to raise the profile of CNS health. Yet, the pace and focus of these efforts differ, creating region-specific opportunities and constraints for developers and providers of CNS therapeutics. Organizations that calibrate their strategies to these nuanced regional realities-rather than relying on one-size-fits-all approaches-are better positioned to address unmet needs while aligning with local regulatory, economic, and cultural conditions.

Competitive dynamics favor companies that blend scientific depth, collaboration, and patient-centric models in CNS therapeutics

The competitive landscape in CNS therapeutics is defined by a mix of large pharmaceutical companies, mid-sized specialists, and emerging biotechs, each bringing distinct capabilities and strategic priorities. Established multinational firms typically maintain broad portfolios that span antidepressants, antipsychotics, anticonvulsants, anesthetics, pain relievers, anxiolytics, and CNS stimulants, leveraging global commercial infrastructures to sustain presence in high-prevalence indications. These companies often focus on lifecycle management, incremental innovation, and geographic expansion, while selectively investing in advanced modalities such as monoclonal antibodies and gene therapies for high-impact neurodegenerative conditions.

In parallel, a wave of specialized biopharmaceutical companies has emerged, concentrating on specific disease clusters or mechanisms of action. Some focus on neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis, aiming to develop disease-modifying or neuroprotective agents using gene therapy, peptide technologies, or next-generation small molecules that cross the blood-brain barrier more effectively. Others specialize in psychiatric disorders, seeking novel approaches to treatment-resistant depression, anxiety disorders, schizophrenia, and bipolar disorder, with an emphasis on rapid onset of action, improved tolerability, and better functional outcomes.

Companies focused on neurovascular diseases and CNS trauma are also gaining visibility, particularly as acute stroke and traumatic brain injury receive increased policy attention due to their long-term disability impact. These organizations often pursue therapies that can be administered quickly in emergency settings, alongside interventions to support neuroregeneration and functional recovery over extended rehabilitation periods. Partnerships with device manufacturers, imaging companies, and digital health firms are common in this segment, reflecting the need for integrated solutions that span diagnosis, acute intervention, and post-acute care.

Across all company types, collaboration and external innovation sourcing are becoming central to strategy. Co-development agreements, licensing deals, and research collaborations with academic centers and technology firms are proliferating, as organizations seek to share risk and accelerate access to novel targets and platforms. Contract development and manufacturing organizations play an increasingly important role, especially for biologics and gene therapies that require specialized facilities and expertise. At the same time, competition for key talent in neurology, psychiatry, data science, and regulatory affairs is intensifying, driving firms to invest in cross-functional teams that can navigate the complexity of CNS research and commercialization.

Market differentiation increasingly hinges on more than clinical trial results alone. Companies are investing in holistic value propositions that incorporate real-world evidence, patient-reported outcomes, digital adherence tools, and support programs for caregivers. In psychiatric disorders and chronic neurodegenerative diseases, where adherence and long-term engagement are crucial, firms that build strong service ecosystems around their therapies gain a competitive edge. Simultaneously, there is growing emphasis on sustainability and supply chain resilience, with leading organizations actively working to mitigate the impact of tariff shifts, raw material constraints, and geopolitical uncertainties on the availability of critical CNS therapies.

Overall, the competitive field is dynamic and fragmented, with room for both large incumbents and agile innovators. Firms that can effectively combine scientific excellence, partnership agility, operational resilience, and patient-centered design are emerging as the most credible contenders in the race to transform CNS care.

Actionable strategies help CNS industry leaders align innovation, resilience, and patient-centric execution for sustained impact

Industry leaders in CNS therapeutics face a pivotal opportunity to convert scientific progress and evolving care models into durable strategic advantage. A first priority is to align research and development portfolios with the most pressing unmet needs across neurodegenerative disorders, psychiatric conditions, neurovascular diseases, and CNS trauma. This requires disciplined assessment of where gene therapy, monoclonal antibodies, peptides, and next-generation small molecules can genuinely shift disease trajectories, as opposed to offering incremental symptom management. Organizations should prioritize indications where mechanistic understanding is advancing rapidly and where regulatory and payer environments exhibit a readiness to accommodate innovative modalities.

At the same time, leaders must strengthen supply chain resilience and tariff awareness, particularly in anticipation of cumulative impacts from United States trade policies in 2025 and beyond. This means diversifying sources for critical inputs, qualifying alternative suppliers across multiple regions, and exploring strategic manufacturing locations that reduce exposure to tariff volatility. Forward-looking companies will integrate tariff scenario planning into long-term manufacturing and procurement strategies, ensuring that pricing, access commitments, and contractual obligations remain viable under a range of cost structures.

Another key recommendation is to deepen integration between clinical development and real-world evidence generation. For CNS disorders, where long-term functional outcomes and quality of life are central, traditional trial endpoints may not fully capture therapeutic value. By incorporating digital biomarkers, remote monitoring, and patient-reported outcomes into both trials and post-marketing programs, companies can build richer evidence packages that resonate with regulators, payers, clinicians, and patient advocacy groups. This approach is particularly valuable in psychiatric disorders and chronic neurodegenerative diseases, where treatment effects may be multidimensional and evolve over extended periods.

Industry leaders should also reimagine commercialization strategies through a patient- and caregiver-centric lens. This involves tailoring therapy access and support models to the realities of hospitals, clinics, and home care environments, and recognizing how offline and online pharmacies contribute differently to adherence and engagement. Dedicated support programs for complex injectables or gene therapies, digital tools that simplify medication routines for cognitive impairment, and education initiatives that address stigma and misperceptions can all enhance uptake and sustained use. In markets where digital health infrastructure is mature, partnerships with telemedicine platforms can extend reach into underserved regions and support earlier intervention.

Finally, organizations must commit to robust stakeholder engagement and policy shaping. CNS conditions place a heavy burden on families, employers, and health systems, and policymakers are increasingly receptive to data-driven proposals that improve diagnosis, treatment access, and long-term support. By collaborating with professional societies, patient advocacy groups, and health authorities, industry leaders can help define standards of care, refine reimbursement frameworks, and promote strategies that recognize the full economic and societal impact of CNS diseases. This proactive stance not only improves the environment for advanced therapies but also positions companies as trusted partners in the broader effort to transform neurological and mental health care.

Robust, multi-source research methodology delivers a nuanced, evidence-driven view of the CNS therapeutics environment

The research methodology underlying this analysis of CNS therapeutics combines multiple complementary approaches to ensure a comprehensive and reliable view of the market environment. At its core is a structured review of peer-reviewed clinical literature, regulatory documents, and policy publications that inform the evolving standards of care across neurodegenerative disorders, psychiatric conditions, neurovascular diseases, and CNS trauma. This includes the systematic examination of data on approved therapies as well as late-stage pipeline assets, with attention to mechanisms of action, routes of administration, safety and efficacy profiles, and real-world utilization patterns where available.

To capture the practical realities of care delivery and therapy adoption, the methodology incorporates detailed assessment of treatment guidelines, formulary practices, and care pathways across hospitals, clinics, and home care settings. Particular focus is placed on how different drug classes-such as antidepressants, antipsychotics, anticonvulsants, anxiolytics, anesthetics, pain relievers, and CNS stimulants-are positioned within these pathways and how advanced modalities like gene therapies, monoclonal antibodies, peptides, and specialized small molecules are being integrated into existing frameworks. This contextual evaluation supports a nuanced understanding of how clinical decisions translate into real-world therapeutic patterns.

Regulatory and policy analysis is another central component of the methodology. By examining approvals, safety communications, guidance documents, and relevant trade and tariff policies, the research traces how agencies and governments are responding to innovation and shaping the risk-benefit and cost-benefit calculus for CNS interventions. The planned 2025 United States tariffs, for example, are reviewed in the context of their implications for pharmaceutical supply chains, manufacturing strategies, and pricing considerations, with particular emphasis on inputs critical to CNS drugs and biologics.

The methodology further integrates a comparative regional perspective, drawing on publicly available information about healthcare infrastructure, reimbursement models, and epidemiological trends in the Americas, Europe, Middle East & Africa, and Asia-Pacific. This comparative lens supports a clear differentiation of regional adoption patterns, access barriers, and innovation hotspots without resorting to speculative quantification. It also allows for a more precise mapping of where specific CNS therapeutic classes and modalities are gaining momentum and where structural constraints limit their diffusion.

Finally, the analysis emphasizes critical synthesis rather than simple aggregation of sources. Contradictory findings in the literature are examined and reconciled when possible, and areas of genuine uncertainty or controversy-such as the long-term impact of some disease-modifying therapies or the scalability of particular gene therapy platforms-are acknowledged. Throughout, the goal is to provide a coherent narrative that aligns scientific evidence, policy developments, and practice realities, equipping decision-makers with a clear, methodologically grounded understanding of the forces shaping the CNS therapeutics landscape.

CNS therapeutics enter a pivotal era where scientific breakthroughs must align with resilience, access, and patient-centered care

Central nervous system therapeutics are entering a period defined by both unprecedented possibility and persistent complexity. Advances in understanding the molecular drivers of neurodegenerative, psychiatric, neurovascular, and traumatic CNS conditions are catalyzing the development of targeted small molecules, gene therapies, monoclonal antibodies, and peptide-based interventions. At the same time, longstanding drug classes such as antidepressants, antipsychotics, anticonvulsants, anesthetics, pain relievers, anxiolytics, and CNS stimulants continue to form the backbone of care, particularly in high-prevalence and resource-constrained settings. The intersection of these traditional and emerging modalities is redefining how clinicians, health systems, and industry players approach CNS disease management.

Yet, scientific progr

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Central Nervous System Therapeutics Market, by Drug Class

  • 8.1. Antidepressants
  • 8.2. Antipsychotics
  • 8.3. Anticonvulsants
  • 8.4. Anxiolytics
  • 8.5. Anesthetics
  • 8.6. Pain Relievers
  • 8.7. CNS Stimulants

9. Central Nervous System Therapeutics Market, by Disease Indication

  • 9.1. Neurodegenerative Disorders
    • 9.1.1. Alzheimer's Disease
    • 9.1.2. Parkinson's Disease
    • 9.1.3. Huntington's Disease
    • 9.1.4. Multiple Sclerosis
  • 9.2. Psychiatric Disorders
    • 9.2.1. Major Depressive Disorder
    • 9.2.2. Anxiety Disorders
    • 9.2.3. Schizophrenia
    • 9.2.4. Bipolar Disorder
  • 9.3. Neurovascular Diseases
    • 9.3.1. Stroke
    • 9.3.2. Cerebral Aneurysm
  • 9.4. CNS Trauma
    • 9.4.1. Traumatic Brain Injury (TBI)
    • 9.4.2. Spinal Cord Injury

10. Central Nervous System Therapeutics Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Transdermal

11. Central Nervous System Therapeutics Market, by Mechanism Of Action

  • 11.1. Gene Therapy
  • 11.2. Monoclonal Antibodies
  • 11.3. Peptides
  • 11.4. Small Molecules

12. Central Nervous System Therapeutics Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Central Nervous System Therapeutics Market, by Distribution Channel

  • 13.1. Offline Pharmacies
  • 13.2. Online Pharmacies

14. Central Nervous System Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Central Nervous System Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Central Nervous System Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Central Nervous System Therapeutics Market

18. China Central Nervous System Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. AC Immune SA
  • 19.7. Acadia Pharmaceuticals, Inc.
  • 19.8. Alkermes plc
  • 19.9. Amgen Inc.
  • 19.10. Anavex Life Sciences Corp.
  • 19.11. Biogen Inc.
  • 19.12. Bristol-Myers Squibb Company
  • 19.13. Eli Lilly and Company
  • 19.14. F. Hoffmann-La Roche Ltd.
  • 19.15. GSK plc
  • 19.16. H. Lundbeck A/S
  • 19.17. Ipsen S.A.
  • 19.18. Jazz Pharmaceuticals plc
  • 19.19. Johnson & Johnson
  • 19.20. Merck & Co., Inc.
  • 19.21. Neumora Therapeutics, Inc.
  • 19.22. Neurocrine Biosciences, Inc.
  • 19.23. Neurona Therapeutics Inc.
  • 19.24. Novartis AG
  • 19.25. Otsuka Pharmaceutical Co., Ltd.
  • 19.26. Pfizer Inc.
  • 19.27. PTC Therapeutics, Inc.
  • 19.28. Sanofi S.A.
  • 19.29. Sumitomo Pharma Co., Ltd.
  • 19.30. Supernus Pharmaceuticals, Inc.
  • 19.31. Takeda Pharmaceutical Company Limited
  • 19.32. Teva Pharmaceutical Industries Ltd.
  • 19.33. UCB S.A.
  • 19.34. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN RELIEVERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN RELIEVERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN RELIEVERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS STIMULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS STIMULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS STIMULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIPOLAR DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIPOLAR DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CEREBRAL ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CEREBRAL ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CEREBRAL ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY (TBI), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY (TBI), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY (TBI), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 224. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 225. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 227. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 254. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 257. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 258. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 260. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 264. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 265. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 267. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 268. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 269. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 271. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES CENTRAL NERVOUS